Surveillance in XXXX .

@entity5 @entity1 @entity189 @entity4797
Treatment results on 695 @entity5 @entity1 followed with surveillance are described. @entity4797 (SGCT) was present in 394 @entity1 and nonseminoma (NSGCT) in 301 @entity1 . Relapses were detected in 155 @entity1 (22%), in 69 @entity1 with SGCT (17%) and 86 with NSGCT (29%). In @entity1 with vascular invasion, relapse was detected in 54% of @entity1 with NSGCT and 38% of @entity1 with SGCT. Time to relapse was median 13 months (range 1 to 84 months) for SGCT and 5 months (range 1 to 171 months) for NSGCT. Forty-nine percent of relapses in SGCT @entity1 were seen within the first year, 87% of the relapses were diagnosed within the first two years, and 98% of the relapses were detected within 5 years. The figures for NSGCT were 80%, 89% and 95%, respectively. Forty-five @entity1 had @entity189 in situ in the contralateral testis, 62% had this together with a @entity4797 in the other testis. Ten @entity1 died during the follow-up period. None of these deaths were caused by the germ cell @entity5 or the treatment. The overall survival for @entity1 with stage I disease is 98.6%, and the cause specific survival 100%.
